

GOLDENBERG DAVID M  
Form 5  
August 14, 2017

**FORM 5**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box if  
no longer subject  
to Section 16.  
Form 4 or Form  
5 obligations  
may continue.  
See Instruction  
1(b).  
Form 3 Holdings  
Reported  
Form 4  
Transactions  
Reported

**ANNUAL STATEMENT OF CHANGES IN BENEFICIAL  
OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0362  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 1.0

1. Name and Address of Reporting Person \*  
**GOLDENBERG DAVID M**

(Last) (First) (Middle)

**C/O IMMUNOMEDICS, INC., 300  
THE AMERICAN ROAD**

(Street)

2. Issuer Name **and** Ticker or Trading  
Symbol  
**IMMUNOMEDICS INC [IMMU]**

3. Statement for Issuer's Fiscal Year Ended  
(Month/Day/Year)  
**06/30/2017**

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify below)

See Remarks

6. Individual or Joint/Group Reporting

(check applicable line)

**MORRIS PLAINS, NJ 07950**

☒ Form Filed by One Reporting Person  
☐ Form Filed by More than One Reporting  
Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/29/2017	Â	A4	Amount 29,239 (1)	(A) or (D) A \$ 0	2,401,054 (2)	D Â
Common Stock	01/29/2017	Â	F4	11,696	D \$ 4.65	2,401,054 (2)	D Â
Common Stock	01/29/2017	Â	A4	29,240 (1)	A \$ 0	3,467,423	I See Footnote (3)
	01/29/2017	Â	F4	11,696	D \$ 4.65	3,467,423	I

Edgar Filing: GOLDENBERG DAVID M - Form 5

Common Stock									See Footnote (3)
Common Stock	03/14/2017	Â	A4	<u>14,620</u> (1)	A	\$ 0	<u>2,401,054</u> (2)	D	Â
Common Stock	03/14/2017	Â	F4	5,848	D	\$ 6.39	<u>2,401,054</u> (2)	D	Â
Common Stock	03/14/2017	Â	A4	<u>14,620</u> (1)	A	\$ 0	3,467,423	I	See Footnote (3)
Common Stock	03/14/2017	Â	F4	5,848	D	\$ 6.39	3,467,423	I	See Footnote (3)
Common Stock	05/18/2017	Â	M4	11,500	A	\$ 3.28	<u>2,401,054</u> (2)	D	Â
Common Stock	05/18/2017	Â	S4	11,500	D	\$ 7.3767	<u>2,401,054</u> (2)	D	Â
Common Stock	05/19/2017	Â	M4	11,500	A	\$ 3.28	<u>2,401,054</u> (2)	D	Â
Common Stock	05/19/2017	Â	S4	11,500	D	\$ 7.3414	<u>2,401,054</u> (2)	D	Â
Common Stock	05/22/2017	Â	M4	11,500	A	\$ 3.28	<u>2,401,054</u> (2)	D	Â
Common Stock	05/22/2017	Â	S4	11,500	D	\$ 7.4548	<u>2,401,054</u> (2)	D	Â
Common Stock	05/25/2017	Â	M4	109,000	A	\$ 3.28	<u>2,401,054</u> (2)	D	Â
Common Stock	05/25/2017	Â	S4	109,000	D	\$ 7.428	<u>2,401,054</u> (2)	D	Â
Common Stock	05/25/2017	Â	M4	106,500	A	\$ 3.28	<u>2,401,054</u> (2)	D	Â
Common Stock	05/18/2017	Â	M4	9,500	A	\$ 3.28	3,467,423	I	See Footnote (3)
Common Stock	05/18/2017	Â	S4	9,500	D	\$ 7.3768	3,467,423	I	See Footnote (3)
Common Stock	05/19/2017	Â	M4	9,500	A	\$ 3.28	3,467,423	I	See Footnote (3)
Common Stock	05/19/2017	Â	S4	9,500	D	\$ 7.4008	3,467,423	I	See Footnote

Common Stock	05/22/2017	Â	M4	9,500	A	\$ 3.28	3,467,423	I	(3) See Footnote (3)
Common Stock	05/22/2017	Â	S4	9,500	D	\$ 7.4508	3,467,423	I	(3) See Footnote (3)
Common Stock	05/25/2017	Â	M4	86,500	A	\$ 3.28	3,467,423	I	(3) See Footnote (3)
Common Stock	05/25/2017	Â	S4	86,500	D	\$ 7.4181	3,467,423	I	(3) See Footnote (3)
Common Stock	05/25/2017	Â	M4	85,000	A	\$ 3.28	3,467,423	I	(3) See Footnote (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 2270  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
					(A) (D)	Date Exercisable Expiration Date	Title Amount Number Shares
Stock Option (right to buy)	\$ 3.28	05/18/2017	Â	M4	Â 11,500	Â (4) 07/23/2017	Common Stock, par value \$0.01 per share 11,500
Stock Option (right to buy)	\$ 3.28	05/19/2017	Â	M4	Â 11,500	Â (4) 07/23/2017	Common Stock, par value \$0.01 per share 11,500
Stock Option (right to buy)	\$ 3.28	05/22/2017	Â	M4	Â 11,500	Â (4) 07/23/2017	Common Stock, par value \$0.01 per share 11,500

Stock Option (right to buy)	\$ 3.28	05/25/2017	Â	M4	Â	109,000	Â <u>(4)</u>	07/23/2017	share Common Stock, par value \$0.01 per share	109,0
Stock Option (right to buy)	\$ 3.28	05/25/2017	Â	M4	Â	106,500	Â <u>(4)</u>	07/23/2017	Common Stock, par value \$0.01 per share	106,5
Stock Option (right to buy)	\$ 3.28	05/18/2017	Â	M4	Â	9,500	Â <u>(5)</u>	07/23/2017	Common Stock, par value \$0.01 per share	9,50
Stock Option (right to buy)	\$ 3.28	05/19/2017	Â	M4	Â	9,500	Â <u>(5)</u>	07/23/2017	Common Stock, par value \$0.01 per share	9,50
Stock Option (right to buy)	\$ 3.28	05/22/2017	Â	M4	Â	9,500	Â <u>(5)</u>	07/23/2017	Common Stock, par value \$0.01 per share	9,50
Stock Option (right to buy)	\$ 3.28	05/25/2017	Â	M4	Â	86,500	Â <u>(5)</u>	07/23/2017	Common Stock, par value \$0.01 per share	86,50
Stock Option (right to buy)	\$ 3.28	05/25/2017	Â	M4	Â	85,000	Â <u>(5)</u>	07/23/2017	Common Stock, par value \$0.01 per share	85,00

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GOLDENBERG DAVID M C/O IMMUNOMEDICS, INC 300 THE AMERICAN ROAD MORRIS PLAINS,Â NJÂ 07950	Â X	Â	Â See Remarks	Â

## Signatures

/s/ David M.  
Goldenberg

08/14/2017

\_\_Signature of Reporting  
Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).  
Represents the settlement of common stock underlying Performance Units that have vested in accordance with the terms of the
- (1) Performance-Based Restricted Stock Unit Agreement entered into by and between the Company and the reporting person on August 16, 2013.
- (2) Includes a total of 190,000 shares held as joint tenants by the reporting person and his spouse, Cynthia L. Goldenberg, also known as Cynthia L. Sullivan, a director of the Issuer.  
Such shares are held by the reporting person's spouse, by various trusts established for the benefit of the reporting person and/or family
- (3) members of the reporting person, or by a majority-owned subsidiary of the Issuer, of which the reporting person is an officer. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interests therein.
- (4) The reporting person was granted stock options pursuant to the Company's 2006 Stock Incentive Plan, as amended. Such stock options vested 25% on the first anniversary of the date of grant and 6.25% on a quarterly basis thereafter.
- (5) The reporting person's spouse, Ms. Cynthia L. Sullivan, was granted stock options pursuant to the Company's 2006 Stock Incentive Plan, as amended. Such stock options vested 25% on the first anniversary of the date grant and 6.25% on a quarterly basis thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.